( <i>S</i> )- <i>N</i> -[1-(3-Morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide:  An Orally Bioavailable KCNQ2 Opener with Significant Activity in a Cortical Spreading Depression Model of Migraine

Yong‐Jin Wu(Bristol-Myers Squibb (Germany)), Steven I. Dworetzky(Bristol-Myers Squibb (United States)), Corinne Greco(Bristol-Myers Squibb (United States)), Li‐Qiang Sun(Bristol-Myers Squibb (United States)), Alexandre L’Heureux(Bristol-Myers Squibb (United States)), Digavalli V. Sivarao(Bristol-Myers Squibb (United States)), Amy Newton(Bristol-Myers Squibb (United States)), Sanna Lehtinen-Oboma(Bristol-Myers Squibb (United States)), Svetlana Tertyshnikova(Bristol-Myers Squibb (United States)), Gene G. Kinney(United States Military Academy), Shing Hong Kang(Bristol-Myers Squibb (United States)), David T. Weaver(University of North Carolina Health Care), Michael Sinz(Rutgers, The State University of New Jersey), Lei Zhang(Bristol-Myers Squibb (United States)), Huan He(University of Kansas), Henry S. Wong(Bristol-Myers Squibb (United States)), David Harden(Bristol-Myers Squibb (United States)), Joanne Natale(Bristol-Myers Squibb (United States)), Mark Thompson(London Metropolitan University), Valentin K. Gribkoff(Bristol-Myers Squibb (United States)), Ronald J. Knox(Bristol-Myers Squibb (United States)), Christopher G. Boissard(Bristol-Myers Squibb (United States))
Journal of Medicinal Chemistry
June 12, 2003
Cited by 55


Related Papers